Janssen
Insider Interview: Paving paths in prostate cancer
May 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer
Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …
Gilead struck anti-competitive deals to retain dominance in HIV market, lawsuit says
May 15, 2019Research and Development AIDS, BMS, Gilead, HIV, Janssen, generic drugs
Gilead Sciences struck anti-competitive deals with Janssen and Britsol-Myers Squibb in an effort to retain dominance in the market for …
Clinical trial will test long acting HIV injection
May 10, 2019Medical Communications Art, CAB, HIV, Janssen, RPV, ViiV, injectable
A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV. The …
Janssen’s Invokana combo smashes primary and secondary endpoints in chronic kidney disease
April 16, 2019Manufacturing and Production, Research and Development Janssen, cardiovascular, chronic kidney disease, diabetes, invokana, pharma
Janssen has unveiled promising new Phase 3 for its sodium-glucose transport (SGLT) protein-2 inhibitor Invokana (canagliflozin), showing that the therapy …
Janssen’s Balversa becomes first FDA-approved FGFR kinase inhibitor for advanced bladder cancer
April 15, 2019Sales and Marketing Balversa, Cancer, FDA, Janssen, bladder cancer, pharma
Janssen’s Balversa (erdafitinib) has become the first FDA-approved fibroblast growth factor receptor (FGFR) kinase inhibitor after the US agency authorised …
Janssen’s Symtuza around 90% effective in achieving undetectable HIV-1 viral loads, when used immediately following diagnosis
April 12, 2019Medical Communications HIV, Janssen, Symtuza, pharma
Janssen has lifted the curtain on data from the first Phase 3 trial investigating the efficacy of Symtuza (darunavir 800mg, …
Janssen closes plant in California, 49 positions axed
April 3, 2019Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, Vacaville, california
Janssen are letting go of 49 employees due to the closure of their plant in Vacaville, California. The Johnson & …
NICE recommends Janssen’s Darzalex myeloma combo
March 12, 2019Manufacturing and Production Janssen, NICE, Velcade, darzalex, myeloma
Britain’s cost effectiveness body NICE have recommended Janssen Pharmaceutical’s Darzalex in combination with Velcade and dexamethasone (DVd), for use within …
Janssen’s party drug-based nasal spray becomes first new FDA-approved depression treatment in 30 years
March 6, 2019Research and Development, Sales and Marketing Janssen, Spravato, depression, esketamine, pharma
The field of depression therapy has seen its biggest leap forward in over three decades, the FDA approval of Janssen’s …
Novartis’ Cosentyx tops Janssen’s Stelara in moderate-to-severe psoriasis trial
March 5, 2019Manufacturing and Production, Research and Development Cosentyx, Janssen, Novartis, Stelara, pharma, psoriasis
New data has been revealed in support of Novartis’ Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis, demonstrating the …
Janssen’s esketamine drug recommended by FDA panel for depression
February 13, 2019Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma
In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …
Janssen seals global inherited retinal disease partnership with gene therapy firm MeiraGTx
February 1, 2019Medical Communications, Research and Development, Sales and Marketing Janssen, MeiraGTx, eye care, gene therapy, pharma
In a bid to boost its portfolio in the eye care space, Janssen has announced a global partnership with clinical-stage …
Janssen’s Erleada meets primary endpoints in ongoing trial into metastatic castration-sensitive prostate cancer
January 31, 2019Research and Development Cancer, Erleada, Janssen, pharma, prostate cancer
Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been …
Imbruvica combo scores expanded FDA approval in most common adult form of leukaemia
January 29, 2019Manufacturing and Production, Sales and Marketing AbbVie, Cancer, Janssen, imbruvica, leukaemia, pharma
It’s big news for Janssen and AbbVie as it emerged that their jointly-developed Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) …
Darzalex “significantly reduces” disease progression and death in multiple myeloma at ASH 2018
December 5, 2018Research and Development ASH 2018, Janssen, darzalex, multiple myeloma, pharma
Janssen has taken the opportunity at the American Society of Hematology (ASH) Annual Meeting 2018 to unveil new Phase 3 …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO
